Glecaprevir / Pibrentasvir

Abbreviation
GLE / PIB
Disease(s)
HCV
Background
.pdf
Patent oppositions filed in
India and Thailand

Glecaprevir / Pibrentasvir combination drugs are used in the treatment of chronic HCV infection.

This drug is missing the following documents, can you help us by contributing something?

Oppositions

Information related to relevant oppositions from around the world.

Patent Oppositions

The table includes oppositions aimed at contesting patents covering this drug. Note that at the country level, several patent applications can cover the same drug.

Please pay attention not only to the patent opposition, but also to the patent application it relates to, see column "Related Patent Application". To better identify similarities, the column "Patent Type" indicates a general classification of the patent. Arguments used to contest a specific type of patent may apply for another that fits in the same category.

CountryDateWho FiledOpposition typeOpposition statusPatent typeRelated patent applicationMore info
Thailand08-07-2022AIDS ACCESS FOUNDATION AND THAI NETWORK FOR PEOPLE WITH HIV/AIDSOtherUnder ExaminationCompositionsWO/2017/015211View/Comment
India28-12-2022Low Cost Standard Therapeutics Pre-GrantUnder ExaminationCombination201817002543View/Comment
India02-10-2021The Delhi Network of Positive PeoplePre-GrantUnder ExaminationCombination201817002543View/Comment

Is something missing? Help us by contributing missing data: Contribute

↑ Back to Top